[{"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-001", "question": "A 52-year-old man with primary sclerosing cholangitis and ulcerative colitis maintained on vedolizumab presents with progressive jaundice, pruritus, and weight loss over 3 months. MRCP shows a dominant stricture at the hepatic hilum with intrahepatic ductal dilation. CA 19-9 is 180 U/mL. Brush cytology from ERCP is suspicious but not diagnostic for malignancy. PET-CT shows FDG avidity at the stricture with standardized uptake value (SUV) max of 6.2. Which of the following is the most appropriate next step in management?", "options": ["Proceed directly to liver transplantation without biopsy confirmation given high suspicion for cholangiocarcinoma in PSC", "Perform endoscopic ultrasound with fine-needle aspiration of the hilar mass", "Initiate neoadjuvant chemoradiation followed by liver transplantation per Mayo Clinic protocol", "Repeat ERCP with cholangioscopy and targeted biopsies of the suspicious area", "Treat as benign dominant stricture with serial stenting and repeat CA 19-9 in 3 months"], "answer": "C", "answer_index": 2, "explanation": "In patients with PSC and suspected hilar cholangiocarcinoma, the Mayo Clinic protocol for neoadjuvant chemoradiation followed by liver transplantation requires strict diagnostic criteria including biopsy confirmation or strongly suggestive findings (CA 19-9 >100 U/mL, malignant-appearing stricture on imaging). PET SUV >5.0 with suspicious cytology meets criteria for protocol enrollment. Direct transplantation without protocol adherence risks transplanting unrecognized metastatic disease. Cholangioscopy and EUS-FNA have higher risks of peritoneal seeding in potentially resectable/transplantable cases.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a PSC patient with suspected hilar cholangiocarcinoma (elevated CA 19-9 >100, PET SUV >5.0, suspicious cytology). Key issue: the stem does not specify whether biopsy confirmation has been obtained or whether the patient meets all Mayo protocol criteria. The keyed answer (C) assumes protocol eligibility without stating this explicitly. However, option D (cholangioscopy with targeted biopsies) is equally defensible because: (1) the stem states cytology is \\\"suspicious but not diagnostic,\\\" suggesting tissue diagnosis is incomplete; (2) Mayo protocol typically requires either definitive cytology/histology OR CA 19-9 >100 with malignant-appearing stricture—the vignette's \\\"suspicious\\\" cytology creates ambiguity about whether diagnostic criteria are met; (3) cholangioscopy offers higher diagnostic yield than brush cytology and is standard practice before committing to transplant protocols. The concern about peritoneal seeding (mentioned in rationale) applies more to EUS-FNA than cholangioscopy. Medical accuracy: The Mayo protocol description is generally accurate, but the item fails to specify whether this patient definitively qualifies. Minimal fix: Add \\\"Multidisciplinary tumor board confirms patient meets Mayo protocol criteria for neoadjuvant therapy\\\" to make C unambiguously correct.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a PSC patient with suspected hilar cholangiocarcinoma (elevated CA 19-9 >100, PET SUV >5.0, suspicious cytology). Key issue: the stem does not specify whether biopsy confirmation has been obtained or whether the patient meets all Mayo protocol criteria. The keyed answer (C) assumes protocol eligibility without stating this explicitly. However, option D (cholangioscopy with targeted biopsies) is equally defensible because: (1) the stem states cytology is \"suspicious but not diagnostic,\" suggesting tissue diagnosis is incomplete; (2) Mayo protocol typically requires either definitive cytology/histology OR CA 19-9 >100 with malignant-appearing stricture—the vignette's \"suspicious\" cytology creates ambiguity about whether diagnostic criteria are met; (3) cholangioscopy offers higher diagnostic yield than brush cytology and is standard practice before committing to transplant protocols. The concern about peritoneal seeding (mentioned in rationale) applies more to EUS-FNA than cholangioscopy. Medical accuracy: The Mayo protocol description is generally accurate, but the item fails to specify whether this patient definitively qualifies. Minimal fix: Add \"Multidisciplinary tumor board confirms patient meets Mayo protocol criteria for neoadjuvant therapy\" to make C unambiguously correct.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-002", "question": "A 38-year-old woman with paroxysmal nocturnal hemoglobinuria (PNH) on eculizumab for 5 years presents with fatigue and dark urine. Laboratory studies show hemoglobin 7.2 g/dL (baseline 10.5), LDH 850 U/L (baseline 300), haptoglobin <10 mg/dL, and negative direct antiglobulin test. She received her last eculizumab dose 12 days ago. Peripheral blood flow cytometry shows 95% PNH clone size (granulocytes). Complement C5 level is undetectable. Which of the following is the most likely explanation for her breakthrough hemolysis?", "options": ["Development of anti-eculizumab antibodies causing drug neutralization", "C5 gene polymorphism (c.2654G→A) resulting in eculizumab-resistant C5", "Concurrent mycoplasma pneumoniae infection with cold agglutinin production", "Functional deficiency of complement factor H due to acquired mutation", "Proximal complement pathway activation via C3 convertase amplification"], "answer": "B", "answer_index": 1, "explanation": "The c.2654G→A polymorphism in the C5 gene results in a single amino acid change (p.Arg885His) that prevents eculizumab binding while maintaining C5 function, leading to breakthrough hemolysis despite adequate drug levels. This autosomal dominant mutation affects approximately 3-4% of Japanese patients and requires switching to ravulizumab or other anti-C5 agents. Anti-drug antibodies are rare with eculizumab. Mycoplasma would cause cold agglutinin disease with positive DAT. Factor H deficiency causes atypical HUS, not PNH exacerbation.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable without additional clinical context. The stem describes breakthrough hemolysis in a PNH patient on eculizumab with undetectable C5 levels and 95% clone size. Key discriminating findings: hemolysis despite therapy, undetectable C5 (suggesting drug present), 12 days post-dose (within therapeutic window), negative DAT. The keyed answer (B: C5 polymorphism) is medically accurate for Japanese populations but requires assuming patient ethnicity—a critical detail absent from the vignette. Without ethnicity, this rare polymorphism (3-4% Japanese, <0.01% other populations) becomes a low-probability diagnosis. Option E (C3 convertase amplification/extravascular hemolysis) is equally defensible as breakthrough hemolysis mechanism in PNH patients on C5 inhibitors, well-documented in literature, and doesn't require ethnicity assumptions. The undetectable C5 finding paradoxically supports both answers: complete C5 blockade can unmask C3-mediated hemolysis, while resistant C5 variants evade detection assays. Option A is less likely (antibodies are rare) but cannot be excluded without anti-drug antibody testing. The stem lacks: patient ethnicity, reticulocyte count, C3d deposition studies, or anti-eculizumab antibody results. Minimal fix: Add 'Patient is of Japanese descent' to make B uniquely defensible, or add C3d/antibody results to discriminate between B/E/A.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable without additional clinical context. The stem describes breakthrough hemolysis in a PNH patient on eculizumab with undetectable C5 levels and 95% clone size. Key discriminating findings: hemolysis despite therapy, undetectable C5 (suggesting drug present), 12 days post-dose (within therapeutic window), negative DAT. The keyed answer (B: C5 polymorphism) is medically accurate for Japanese populations but requires assuming patient ethnicity—a critical detail absent from the vignette. Without ethnicity, this rare polymorphism (3-4% Japanese, <0.01% other populations) becomes a low-probability diagnosis. Option E (C3 convertase amplification/extravascular hemolysis) is equally defensible as breakthrough hemolysis mechanism in PNH patients on C5 inhibitors, well-documented in literature, and doesn't require ethnicity assumptions. The undetectable C5 finding paradoxically supports both answers: complete C5 blockade can unmask C3-mediated hemolysis, while resistant C5 variants evade detection assays. Option A is less likely (antibodies are rare) but cannot be excluded without anti-drug antibody testing. The stem lacks: patient ethnicity, reticulocyte count, C3d deposition studies, or anti-eculizumab antibody results. Minimal fix: Add 'Patient is of Japanese descent' to make B uniquely defensible, or add C3d/antibody results to discriminate between B/E/A.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-003", "question": "A 67-year-old man who underwent orthotopic liver transplantation 4 months ago for HCV cirrhosis presents with fever, cough, and hypoxemia. He is on tacrolimus and prednisone 5 mg daily. Chest CT shows multiple nodular opacities with surrounding ground-glass halos. Bronchoalveolar lavage PCR is positive for Torque teno virus (TTV) DNA at 10^8 copies/mL. Blood TTV viral load is 10^7 copies/mL. Which of the following is the most appropriate interpretation and management?", "options": ["TTV indicates severe immunosuppression; reduce tacrolimus dose and monitor for resolution", "TTV is a direct pulmonary pathogen; initiate intravenous ribavirin therapy", "TTV reactivation suggests CMV co-infection; start ganciclovir empirically", "TTV viral load has no clinical significance in this setting; pursue alternative diagnoses", "TTV indicates possible donor-derived infection; perform lung biopsy for histopathology"], "answer": "A", "answer_index": 0, "explanation": "Torque teno virus (TTV) viral load serves as a functional biomarker of overall immunosuppression in transplant recipients, with high levels indicating excessive immunosuppression and increased risk of opportunistic infections. The radiographic findings suggest invasive fungal infection (e.g., aspergillosis) in an over-immunosuppressed host. Reducing immunosuppression while evaluating for fungal pathogens is appropriate. TTV itself is not a pulmonary pathogen. There is no established antiviral therapy for TTV, and it does not specifically indicate CMV co-infection or donor-derived infection.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - a different answer is more defensible. The vignette describes a post-transplant patient with fever, cough, hypoxemia, and CT findings of nodular opacities with ground-glass halos - classic for invasive fungal infection (likely aspergillosis) in an immunosuppressed host. While the rationale correctly states TTV is a biomarker of immunosuppression (not a pathogen), the keyed answer (A) focuses on reducing tacrolimus based on TTV levels, which is not standard practice. TTV viral load monitoring is investigational and not routinely used to guide immunosuppression adjustments. The clinical presentation demands immediate evaluation for life-threatening opportunistic infections (fungal, bacterial, viral). Option D is more defensible: TTV has no established clinical utility in guiding management; the priority is pursuing alternative diagnoses (fungal cultures, galactomannan, beta-D-glucan, possibly empiric antifungals). The stem findings strongly suggest invasive aspergillosis requiring urgent diagnostic workup and treatment, not immunosuppression reduction based on an investigational biomarker. Main medical issue: TTV is not validated for clinical decision-making in this context. Main logical issue: Key misidentifies the best answer given standard transplant infectious disease management. Minimal fix: Change key to D or reframe stem to explicitly state TTV-guided immunosuppression protocols are institutional standard.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - a different answer is more defensible. The vignette describes a post-transplant patient with fever, cough, hypoxemia, and CT findings of nodular opacities with ground-glass halos - classic for invasive fungal infection (likely aspergillosis) in an immunosuppressed host. While the rationale correctly states TTV is a biomarker of immunosuppression (not a pathogen), the keyed answer (A) focuses on reducing tacrolimus based on TTV levels, which is not standard practice. TTV viral load monitoring is investigational and not routinely used to guide immunosuppression adjustments. The clinical presentation demands immediate evaluation for life-threatening opportunistic infections (fungal, bacterial, viral). Option D is more defensible: TTV has no established clinical utility in guiding management; the priority is pursuing alternative diagnoses (fungal cultures, galactomannan, beta-D-glucan, possibly empiric antifungals). The stem findings strongly suggest invasive aspergillosis requiring urgent diagnostic workup and treatment, not immunosuppression reduction based on an investigational biomarker. Main medical issue: TTV is not validated for clinical decision-making in this context. Main logical issue: Key misidentifies the best answer given standard transplant infectious disease management. Minimal fix: Change key to D or reframe stem to explicitly state TTV-guided immunosuppression protocols are institutional standard.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-004", "question": "A 44-year-old woman with autoimmune hepatitis-primary biliary cholangitis overlap syndrome on ursodeoxycholic acid and budesonide develops recurrent episodes of severe, cramping abdominal pain with diarrhea occurring 30-60 minutes after meals. Symptoms improve with fasting. CT angiography shows no mesenteric ischemia. Gastric emptying study is normal. Upper endoscopy with duodenal biopsies shows villous blunting and intraepithelial lymphocytes. Serum tryptase during an episode is 45 ng/mL (normal <11.4). Which of the following is the most likely diagnosis?", "options": ["Mesenteric venous thrombosis with portal hypertensive enteropathy", "Systemic mastocytosis with gastrointestinal involvement", "Celiac disease with refractory sprue", "Abdominal angina from median arcuate ligament syndrome", "Bile acid malabsorption due to ileal dysfunction"], "answer": "B", "answer_index": 1, "explanation": "Systemic mastocytosis can present with postprandial abdominal pain, diarrhea, and flushing due to mast cell mediator release triggered by food. Elevated serum tryptase (>20 ng/mL) during symptoms is diagnostic. The duodenal findings represent mast cell infiltration rather than celiac disease. Mesenteric ischemia was ruled out by CT angiography. Median arcuate ligament syndrome causes epigastric pain but not diarrhea or elevated tryptase. Bile acid malabsorption does not explain the elevated tryptase or timing of symptoms.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes postprandial cramping abdominal pain with diarrhea (30-60 minutes after meals), improving with fasting, in a patient with elevated serum tryptase (45 ng/mL, normal <11.4) during symptoms. Key discriminating findings: (1) markedly elevated tryptase during symptomatic episode (>20 ng/mL is highly suggestive of systemic mastocytosis), (2) postprandial timing with fasting improvement (mast cell mediator release triggered by food), (3) duodenal villous blunting with intraepithelial lymphocytes (mast cell infiltration can mimic celiac histology), (4) CT angiography ruling out mesenteric ischemia, (5) normal gastric emptying. Option B (systemic mastocytosis) is uniquely supported by the elevated tryptase, which is the key diagnostic finding. Option C (celiac disease) would not explain the markedly elevated tryptase or the specific postprandial timing. Option A lacks evidence of thrombosis on imaging. Option D was excluded by normal CT angiography. Option E does not explain elevated tryptase or the duodenal histology. The item is logically valid with a single defensible best answer matching the key. Medical accuracy is excellent; elevated tryptase during symptoms is a well-established diagnostic criterion for systemic mastocytosis. No fix needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes postprandial cramping abdominal pain with diarrhea (30-60 minutes after meals), improving with fasting, in a patient with elevated serum tryptase (45 ng/mL, normal <11.4) during symptoms. Key discriminating findings: (1) markedly elevated tryptase during symptomatic episode (>20 ng/mL is highly suggestive of systemic mastocytosis), (2) postprandial timing with fasting improvement (mast cell mediator release triggered by food), (3) duodenal villous blunting with intraepithelial lymphocytes (mast cell infiltration can mimic celiac histology), (4) CT angiography ruling out mesenteric ischemia, (5) normal gastric emptying. Option B (systemic mastocytosis) is uniquely supported by the elevated tryptase, which is the key diagnostic finding. Option C (celiac disease) would not explain the markedly elevated tryptase or the specific postprandial timing. Option A lacks evidence of thrombosis on imaging. Option D was excluded by normal CT angiography. Option E does not explain elevated tryptase or the duodenal histology. The item is logically valid with a single defensible best answer matching the key. Medical accuracy is excellent; elevated tryptase during symptoms is a well-established diagnostic criterion for systemic mastocytosis. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-005", "question": "A 62-year-old man with essential thrombocythemia (JAK2 V617F-positive) on hydroxyurea presents with acute onset of severe headache and right hemiparesis. CT head shows left middle cerebral artery territory infarction. Platelet count is 450,000/μL. MRI brain with contrast reveals multiple small enhancing lesions in both cerebral hemispheres. Transthoracic echocardiogram shows no vegetations. Blood cultures are negative. Which of the following is the most likely underlying mechanism for his stroke?", "options": ["Nonbacterial thrombotic endocarditis from hypercoagulable state", "Leukoencephalopathy from hydroxyurea toxicity", "Transformation to acute myeloid leukemia with CNS involvement", "Cerebral vasculitis secondary to JAK2 mutation", "Paradoxical embolism through patent foramen ovale"], "answer": "A", "answer_index": 0, "explanation": "Myeloproliferative neoplasms, particularly essential thrombocythemia, can cause nonbacterial thrombotic endocarditis (NBTE) with sterile vegetations that embolize to cerebral arteries. The multiple enhancing brain lesions represent septic emboli analogs from NBTE. Hydroxyurea leukoencephalopathy causes symmetric white matter changes without enhancing lesions. AML transformation would show blasts in blood or marrow. Cerebral vasculitis is not associated with JAK2 mutations. Paradoxical embolism would not explain multiple enhancing lesions without a venous source.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a JAK2+ ET patient on hydroxyurea with acute stroke (left MCA territory) and multiple small enhancing lesions bilaterally. Key discriminating findings: platelet count 450,000/μL (controlled), negative blood cultures, no vegetations on TTE, multiple enhancing lesions. The keyed answer (A: NBTE) is problematic because: (1) TTE shows NO vegetations, contradicting the diagnosis of endocarditis; (2) NBTE vegetations are typically small and may be missed on TTE, but the stem explicitly states \\\"no vegetations,\\\" making this diagnosis unsupported; (3) the rationale incorrectly calls enhancing lesions \\\"septic emboli analogs\\\"—NBTE produces bland thromboemboli, not enhancing lesions which suggest infection/inflammation. Option D (cerebral vasculitis) is equally defensible: JAK2+ MPNs are associated with inflammatory/autoimmune phenomena; multiple enhancing lesions fit vasculitis better than bland emboli; the negative cultures and absence of vegetations support a non-infectious inflammatory process. The item is underspecified (no vessel imaging, CSF, or biopsy to distinguish vasculitis from embolic disease) leading to multiple defensible answers. Main medical issue: NBTE does not cause enhancing lesions and requires vegetations. Minimal fix: Add TEE showing small vegetations OR change imaging to \\\"multiple acute infarcts without enhancement\\\" to support NBTE.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a JAK2+ ET patient on hydroxyurea with acute stroke (left MCA territory) and multiple small enhancing lesions bilaterally. Key discriminating findings: platelet count 450,000/μL (controlled), negative blood cultures, no vegetations on TTE, multiple enhancing lesions. The keyed answer (A: NBTE) is problematic because: (1) TTE shows NO vegetations, contradicting the diagnosis of endocarditis; (2) NBTE vegetations are typically small and may be missed on TTE, but the stem explicitly states \"no vegetations,\" making this diagnosis unsupported; (3) the rationale incorrectly calls enhancing lesions \"septic emboli analogs\"—NBTE produces bland thromboemboli, not enhancing lesions which suggest infection/inflammation. Option D (cerebral vasculitis) is equally defensible: JAK2+ MPNs are associated with inflammatory/autoimmune phenomena; multiple enhancing lesions fit vasculitis better than bland emboli; the negative cultures and absence of vegetations support a non-infectious inflammatory process. The item is underspecified (no vessel imaging, CSF, or biopsy to distinguish vasculitis from embolic disease) leading to multiple defensible answers. Main medical issue: NBTE does not cause enhancing lesions and requires vegetations. Minimal fix: Add TEE showing small vegetations OR change imaging to \"multiple acute infarcts without enhancement\" to support NBTE.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-006", "question": "A 31-year-old hematopoietic stem cell transplant recipient (day +45) for AML develops new-onset confusion and myoclonus. MRI brain shows symmetric T2 hyperintensities in the thalami and periaqueductal gray matter. CSF shows 5 WBCs/μL, protein 65 mg/dL, glucose 60 mg/dL (serum 95 mg/dL). CSF PCR for HSV, VZV, EBV, CMV, and HHV-6 are negative. Metagenomic next-generation sequencing of CSF detects Astrovirus VA1/HMO-C RNA. Which of the following is the most appropriate management?", "options": ["Intravenous immunoglobulin 2 g/kg divided over 2-5 days", "Oral nitazoxanide 500 mg twice daily for 14 days", "Reduce immunosuppression and provide supportive care", "Intravenous ribavirin loading dose 33 mg/kg then 16 mg/kg every 6 hours", "Intrathecal administration of foscarnet 40 mg twice weekly"], "answer": "C", "answer_index": 2, "explanation": "Astrovirus VA1/HMO-C encephalitis in immunocompromised hosts has no proven antiviral therapy. Reduction of immunosuppression to allow immune reconstitution is the mainstay of management, along with supportive care. Intravenous immunoglobulin has been used but lacks proven efficacy. Nitazoxanide has in vitro activity but no clinical data in CNS infections. Ribavirin has poor CNS penetration and no proven benefit. Intrathecal foscarnet is used for HSV/VZV encephalitis but not for astrovirus.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a post-HSCT patient (day +45) with encephalitis (confusion, myoclonus, symmetric thalamic/periaqueductal T2 hyperintensities) and CSF metagenomic sequencing identifying Astrovirus VA1/HMO-C. Key discriminating findings: immunocompromised state, negative standard viral PCRs, specific astrovirus detection. The clinical problem asks for most appropriate management of astrovirus encephalitis in an immunocompromised host. Option C (reduce immunosuppression + supportive care) is the established approach for viral CNS infections in transplant recipients when no proven antiviral exists, allowing immune reconstitution. Option A (IVIG) has anecdotal use but lacks proven efficacy for astrovirus. Option B (nitazoxanide) treats gastrointestinal astrovirus but has no CNS penetration data or clinical evidence for encephalitis. Option D (ribavirin) has poor CNS penetration and no astrovirus efficacy data. Option E (intrathecal foscarnet) is inappropriate—foscarnet targets herpesviruses, not astrovirus. The keyed answer aligns with current management principles for opportunistic viral CNS infections without specific antivirals. Medical accuracy is high; the approach reflects standard transplant infectious disease practice. Minimal fix: None needed; item is logically valid and medically sound.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a post-HSCT patient (day +45) with encephalitis (confusion, myoclonus, symmetric thalamic/periaqueductal T2 hyperintensities) and CSF metagenomic sequencing identifying Astrovirus VA1/HMO-C. Key discriminating findings: immunocompromised state, negative standard viral PCRs, specific astrovirus detection. The clinical problem asks for most appropriate management of astrovirus encephalitis in an immunocompromised host. Option C (reduce immunosuppression + supportive care) is the established approach for viral CNS infections in transplant recipients when no proven antiviral exists, allowing immune reconstitution. Option A (IVIG) has anecdotal use but lacks proven efficacy for astrovirus. Option B (nitazoxanide) treats gastrointestinal astrovirus but has no CNS penetration data or clinical evidence for encephalitis. Option D (ribavirin) has poor CNS penetration and no astrovirus efficacy data. Option E (intrathecal foscarnet) is inappropriate—foscarnet targets herpesviruses, not astrovirus. The keyed answer aligns with current management principles for opportunistic viral CNS infections without specific antivirals. Medical accuracy is high; the approach reflects standard transplant infectious disease practice. Minimal fix: None needed; item is logically valid and medically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]